Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31.
Discover how strategic lean projects can help AV integrators come out stronger when the market accelerates again.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback